
1. lancet infect dis. 2019 sep;19(9):1001-1012. doi: 10.1016/s1473-3099(19)30310-x. 
epub 2019 aug 6.

safety efficacy inactivated varicella zoster virus vaccine in
immunocompromised patients malignancies: two-arm, randomised,
double-blind, phase 3 trial.

mullane km(1), morrison va(2), camacho lh(3), arvin a(4), mcneil sa(5), durrand
j(6), campbell b(6), su sc(6), chan isf(6), parrino j(6), kaplan ss(6),
popmihajlov z(6), annunziato pw(6); v212 protocol 011 trial team.

collaborators: cerana s, dictar mo, bonvehi p, tregnaghi jp, fein l, ashley d,
singh m, hayes t, playford g, morrissey o, thaler j, kuehr t, greil r,
pecherstorfer m, duck l, van eygen k, aoun m, de prijck b, franke fa, barrios c, 
mendes a, serrano sv, garcia rf, moore f, camargo j, pires la, alves rs, radinov 
a, oreshkov k, minchev v, hubenova ai, koynova t, ivanov i, rabotilova b, minchev
v, petrov pa, chilingirov p, karanikolov s, raynov j, grimard d, mcneil s, kumar 
d, larratt lm, weiss k, delage r, diaz-mitoma fj, cano po, couture f, carvajal p,
yepes a, torres ulloa r, fardella p, caglevic c, rojas c, orellana e, gonzalez p,
acevedo a, galvez km, gonzalez me, franco s, restrepo jg, rojas ca, bonilla c,
florez le, ospina av, manneh r, zorica r, vrdoljak dv, samarzija m, petruzelka l,
vydra j, mayer j, cibula d, prausova j, paulson g, ontaneda m, palk k, vahlberg
a, rooneem r, galtier f, postil d, lucht f, laine f, launay o, laurichesse h,
duval x, cornely oa, camerer b, panse j, zaiss m, derigs hg, menzel h, verbeek m,
georgoulias v, mavroudis d, anagnostopoulos a, terpos e, cortes d, umanzor j,
bejarano s, galeano rw, wong r, hui p, pedrazzoli p, ruggeri l, aversa f, bosi a,
gentile g, rambaldi a, contu a, marei l, abbadi a, hayajneh w, kattan j, farhat
f, chahine g, rutkauskiene j, marfil rivera lj, lopez chuken ya, franco
villarreal h, lopez hernandez j, blacklock h, lopez ri, alvarez r, gomez am,
quintana ts, moreno larrea m, zorrilla sj, alarcon e, samanez f, caguioa pb,
tiangco bj, mora em, betancourt-garcia rd, hallman-navarro d, feliciano-lopez lj,
velez-cortes ha, cabanillas f, ganea de, ciuleanu te, ghizdavescu dg, miron l,
cebotaru cl, cainap ci, anghel r, dvorkin mv, gladkov oa, fadeeva nv, kuzmin aa, 
lipatov on, zbarskaya ii, akhmetzyanov fs, litvinov iv, afanasyev bv, cherenkova 
m, lioznov d, lisukov ia, smirnova ya, kolomietz s, halawani h, goh yt, drgona l,
chudej j, matejkova m, reckova m, rapoport bl, szpak wm, malan dr, jonas n, jung 
cw, lee dg, yoon ss, lopez jimenez j, duran martinez i, rodriguez moreno jf,
solano vercet c, de la camara r, batlle massana m, yeh sp, chen cy, chou hh, tsai
cm, chiu ch, siritanaratkul n, norasetthada l, sriuranpong v, seetalarom k, akan 
h, dane f, ozcan ma, ozsan gh, kalayoglu besisik sf, cagatay a, yalcin s, peniket
a, mullan sr, dakhil km, sivarajan k, suh jg, sehgal a, marquez f, gomez eg,
mullane mr, skinner wl, behrens rj, trevarthe dr, mazurczak ma, lambiase ea,
vidal ca, anac sy, rodrigues ga, baltz b, boccia r, wertheim ms, holladay cs,
zenk d, fusselman w, wade iii jl, jaslowsk aj, keegan j, robinson mo, go rs,
farnen j, amin b, jurgens d, risi gf jr, beatty pg, naqvi t, parshad s, hansen
vl, ahmed m, steen pd, badarinath s, dekker a, scouros ma, young de, graydon
harker w, kendall sd, citron ml, chedid s, posada jg jr, gupta mk, rafiyath s,
buechler-price j, sreenivasappa s, chay ch, burke jm, young se, mahmood a, kugler
jw, gerstner g, fuloria j, belman nd, geller r, nieva j, whittenberger bp, wong
b, cescon tp, abesada-terk g jr, guarino mj, zweibach a, ibrahim en, takahashi g,
garrison ma, mowat rb, choi bs, oliff ia, singh j, guter ka, ayrons k, rowland
km, noga sj, rao sb, columbie a, nualart mt, cecchi gr, campos lt, mohebtash m,
flores mr, rothstein-rubin r, o'connor bm, soori g, knapp m, miranda fg, goodgame
bw, kassem m, belani r, sharma s, ortiz t, sonneborn hl, markowitz ab, wilbur d, 
meiri e, koo vs, jhangiani hs, wong l, sanani s, lawrence sj, jones cm, murray c,
papageorgiou c, gurtler js, ascensao jl, seetalarom k, venigalla ml, d'andrea m, 
de las casas c, haile dj, qazi fu, santander jl, thomas mr, rao vp, craig m, garg
rj, robles r, lyons rm, stegemoller rk, goel s, garg s, lowry p, lynch c, lash b,
repka t, baker j, goueli bs, campbell tc, van echo da, lee yj, reyes ea, senecal 
fm, donnelly g, byeff p, weiss r, reid t, roeland e, goel a, prow dm, brandt ds, 
kaplan hg, payne je, boeckh mg, rosen pj, mena rr, khan r, betts rf, sharp sa,
morrison va, fitz-patrick d, congdon j, erickson n, abbasi r, henderson s, mehdi 
a, wos ej, rehmus e, beltzer l, tamayo ra, mahmood t, reboli ac, moore a, brown
jm, cruz j, quick dp, potz jl, kotz kw, hutchins m, chowhan nm, devabhaktuni yd, 
braly p, berenguer ra, shambaugh sc, o'rourke tj, conkright wa, winkler cf, addo 
f, duic jp, high kp, kutner me, collins r, carrizosa dr, perry dj, kailath e,
rosen n, sotolongo r, shoham s, chen t.

author information: 
(1)university chicago, department medicine, chicago, il, usa. electronic
address: kmullane@medicine.bsd.uchicago.edu.
(2)university minnesota, hennepin county medical center, minneapolis, mn, usa.
(3)oncology consultants, houston, tx, usa.
(4)stanford university school medicine, stanford, ca, usa.
(5)canadian center vaccinology, iwk health centre nova scotia health
authority, dalhousie university, halifax, ns, canada.
(6)merck & co, inc, kenilworth, nj, usa.

erratum in
    lancet infect dis. 2019 aug 23;:.

comment in
    lancet infect dis. 2019 sep;19(9):922-924.

background: patients immunocompromised malignancy an
increased risk herpes zoster herpes zoster-related complications. aimed
to investigate efficacy safety inactivated varicella zoster virus
(vzv) vaccine herpes zoster prevention patients solid tumour or
haematological malignancies.
methods: phase 3, two-arm, randomised, double-blind, placebo-controlled,
multicentre trial adaptive design done 329 centres across 40
countries. trial included adult patients solid tumour malignancies
receiving chemotherapy haematological malignancies, either
receiving receiving chemotherapy. patients randomly assigned (1:1) to
receive four doses vzv vaccine inactivated γ irradiation placebo
approximately 30 days apart. patients, investigators, trial site staff,
clinical adjudication committee, sponsor's clinical laboratory personnel 
were masked group assignment. primary efficacy endpoint herpes
zoster incidence patients solid tumour malignancies receiving
chemotherapy, assessed modified intention-to-treat population
(defined randomly assigned patients received least one dose of
inactivated vzv vaccine placebo). primary safety endpoint serious
adverse events 28 days fourth dose patients solid tumour 
malignancies receiving chemotherapy. safety endpoints assessed all
patients received least one dose inactivated vzv vaccine placebo and
had follow-up data. trial registered (nct01254630 eudract
2010-023156-89).
findings: june 27, 2011, april 11, 2017, 5286 patients randomly 
assigned receive vzv vaccine inactivated γ irradiation (n=2637) placebo 
(n=2649). haematological malignancy arm terminated early of
evidence futility planned interim analysis; therefore, prespecified
haematological malignancy endpoints deemed exploratory. patients with
solid tumour malignancies modified intention-to-treat population,
confirmed herpes zoster occurred 22 1328 (6·7 per 1000 person-years) vzv
vaccine recipients 61 1350 (18·5 per 1000 person-years) placebo
recipients. estimated vaccine efficacy herpes zoster patients with
solid tumour malignancies 63·6% (97·5% ci 36·4 79·1), meeting the
prespecified success criterion. patients solid tumour malignancies,
serious adverse events similar frequency across treatment groups,
occurring 298 (22·5%) 1322 patients received vaccine 283
(21·0%) 1346 patients received placebo (risk difference 1·5%, 95% ci -1·7 
to 4·6). vaccine-related serious adverse events less 1% each
treatment group. vaccine-related injection-site reactions common the
vaccine group placebo group. haematological malignancy group, 
vzv vaccine well tolerated estimated vaccine efficacy herpes
zoster 16·8% (95% ci -17·8 41·3).
interpretation: inactivated vzv vaccine well tolerated efficacious
for herpes zoster prevention patients solid tumour malignancies receiving
chemotherapy, efficacious herpes zoster prevention patients
with haematological malignancies.
funding: merck & co, inc.

copyright © 2019 elsevier ltd. rights reserved.

doi: 10.1016/s1473-3099(19)30310-x 
pmid: 31399378  [indexed medline]

